← All countries · Americas
81.8%
MCV1
2025 · Administrative (country-reported)
93.4%
DTP3
2025 · Administrative (country-reported)
91.9%
IPV complete
2025 · Administrative (country-reported)
93.4%
HepB3
2025 · Administrative (country-reported)
0
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 94.8%2025 · Administrative (country-reported) | 94.8% | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 91.9%2025 · Administrative (country-reported) | 91.9% | D · poor | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 93.4%2025 · Administrative (country-reported) | 93.4% | D · poor | |
| IPV1First dose of inactivated polio vaccine | 89.7%2025 · Administrative (country-reported) | 89.7% | D · poor | |
| IPV completeInactivated polio vaccine, complete primary series | 91.9%2025 · Administrative (country-reported) | 91.9% | D · poor | |
| MCV1First dose of measles-containing vaccine | 81.8%2025 · Administrative (country-reported) | 81.8% | D · poor | |
| MCV2Second dose of measles-containing vaccine | 87.7%2025 · Administrative (country-reported) | 87.7% | D · poor | |
| RCV1First dose of rubella-containing vaccine | 81.8%2025 · Administrative (country-reported) | 81.8% | D · poor | |
| HepB3Third dose of hepatitis B vaccine | 93.4%2025 · Administrative (country-reported) | 93.4% | D · poor | |
| HepB birthHepatitis B birth dose within 24 hours | 96.5%2025 · Administrative (country-reported) | 96.5% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 93.4%2025 · Administrative (country-reported) | 93.4% | D · poor | |
| PCV1Pneumococcal conjugate vaccine, first dose | 91.9%2025 · Administrative (country-reported) | 91.9% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 91.9%2025 · Administrative (country-reported) | 91.9% | D · poor | |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | 0%2022 · Administrative (country-reported) | 0% | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Pertussis (whooping cough) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | C · weak | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (52 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | birth - 11 months |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTWPDTwP (Whole cell) vaccine | 4 | M18 | General/routine | |
| DTWPDTwP (Whole cell) vaccine | 5 | Y4-Y5 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 1 | M2 | General/routine | |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 2 | M4 | General/routine | |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 3 | M6 | General/routine | |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 4 | M18 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Adults | adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Adults | adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Health workers | adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Adults | adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory) |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | at birth up to 24 hrs. after birth |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | <Y25 | Catch-up adults | Single dose is offered to males and females ages 9-15+. (one dose also offered to older females up to 25 years of age) |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | <Y25 | Catch-up children | Single dose is offered to males and females ages 9-15+. (one dose also offered to older females up to 25 years of age) |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y9-Y15 | HPV administered to females and males | Single dose is offered to males and females ages 9-15+. (one dose also offered to older females up to 25 years of age) |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons +65 age group |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 1 | M2 | General/routine | 2 Months to 18 months |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | 2 Months to 18 months |
| IPVIPV (Inactivated polio vaccine) | 3 | M6 | General/routine | 2 Months to 18 months |
| IPVIPV (Inactivated polio vaccine) | 4 | M18 | General/routine | 2 Months to 18 months |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Y1 | General/routine | 12 month old and 24 months old |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y2 | General/routine | 12 month old and 24 months old |
| OPVOPV (Oral polio vaccine) | 2 | M4 | General/routine | |
| OPVOPV (Oral polio vaccine) | 4 | M18 | General/routine | |
| OPVOPV (Oral polio vaccine) | 5 | Y4-Y5 | General/routine | |
| OPVOPV (Oral polio vaccine) | 6 | Y15 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M6 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 4 | M18 | General/routine | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | >Y4 | Risk group(s) | Children over 4 yrs of age and older with incomplete vaccinations/history of febrile seizers. Adults travelers, Adults with unknown previous vaccination history |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Travellers | Adults travelers | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Adults | older children and adults |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +W4 | Adults | older children and adults |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6-Y1 | Adults | older children and adults |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y15 | General/routine | 15 yrs |
| VARICELLAVaricella vaccine | 1 | M15 | General/routine | |
| VARICELLAVaricella vaccine | 2 | Y4-Y5 | General/routine | |
| YFYF (Yellow fever) vaccine | 1 | 1st contact | Travellers | travellers |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.